Identification of TRAPPC8 as a host factor required for human papillomavirus cell entry

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Ishii, Yoshiyuki ^a   Nakahara, Tomomi ^b   Kataoka, Michiyo ^a   Kusumoto Matsuo, Rika ^a   Mori, Seiichiro ^a   Takeuchi, Takamasa ^a   Kukimoto, Iwao ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRAPPC8 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HELA CELL LINE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM; PAPILLOMA VIRUS; PATHOGENICITY; PHYSIOLOGY; TRANS GOLGI NETWORK; WESTERN BLOTTING;

BLOTTING, WESTERN; FLOW CYTOMETRY; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICROSCOPY, FLUORESCENCE; PAPILLOMAVIRIDAE; TRANS-GOLGI NETWORK; VESICULAR TRANSPORT PROTEINS;

EID: 84893553938     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080297     Document Type: Article

References (60)

1. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82: 5190-5197. (Pubitemid 351705228)
2. de Villiers EM (2013) Cross-roads in the classification of papillomaviruses. Virology 445: 2-10.
3. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285. (Pubitemid 38924707)
4. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2: e69.
5. Combita AL, Touze A, Bousarghin L, Sizaret PY, Munoz N, et al. (2001) Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204: 183-188. (Pubitemid 33000054)
6. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570. (Pubitemid 32094716)
7. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
8. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, et al. (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274: 5810-5822. (Pubitemid 29109237)
9. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND (2006) Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol 80: 8940-8950. (Pubitemid 44359968)
10. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77: 12961-12967. (Pubitemid 37494291)
11. Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103: 1522-1527. (Pubitemid 43191198)
12. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT (2008) Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 82: 4638-4646. (Pubitemid 351563700)
13. Day PM, Lowy DR, Schiller JT (2003) Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307: 1-11. (Pubitemid 36355861)
14. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP (2010) Mechanisms of cell entry by human papillomaviruses: an overview. Virol J 7: 11.
15. Laniosz V, Dabydeen SA, Havens MA, Meneses PI (2009) Human papillomavirus type 16 infection of human keratinocytes requires clathrin and caveolin-1 and is brefeldin a sensitive. J Virol 83: 8221-8232.
16. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, et al. (2013) The Evolving Field of Human Papillomavirus Receptor Research: A Review of Binding and Entry. J Virol.
17. Sapp M, Bienkowska-Haba M (2009) Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J 276: 7206-7216.
18. Schelhaas M, Ewers H, Rajamaki ML, Day PM, Schiller JT, et al. (2008) Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog 4: e1000148.
19. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, et al. (2012) Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8: e1002657.
20. Schiller JT, Day PM, Kines RC (2010) Current understanding of the mechanism of HPV infection. Gynecol Oncol 118: S12-17.
21. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, et al. (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71: 2449-2456. (Pubitemid 27078628)
22. McMillan NA, Payne E, Frazer IH, Evander M (1999) Expression of the alpha6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virology 261: 271-279. (Pubitemid 29431779)
23. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, et al. (2008) Clathrin-and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3: e3313.
24. Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, et al. (2013) Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87: 3435-3446.
25. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, et al. (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7: e43519.
26. Dziduszko A, Ozbun MA (2013) Annexin A2 and S100A10 Regulate Human Papillomavirus Type 16 Entry and Intracellular Trafficking in Human Keratinocytes. J Virol 87: 7502-7515.
27. Huang HS, Buck CB, Lambert PF (2010) Inhibition of gamma secretase blocks HPV infection. Virology 407: 391-396.
28. Karanam B, Peng S, Li T, Buck C, Day PM, et al. (2010) Papillomavirus infection requires gamma secretase. J Virol 84: 10661-10670.
29. Bienkowska-Haba M, Patel HD, Sapp M (2009) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5: e1000524.
30. Surviladze Z, Dziduszko A, Ozbun MA (2012) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 8: e1002519.
31. Spoden G, Kuhling L, Cordes N, Frenzel B, Sapp M, et al. (2013) Human papillomavirus types 16, 18, and 31 share similar endocytic requirements for entry. J Virol 87: 7765-7773.
32. Smith JL, Campos SK, Wandinger-Ness A, Ozbun MA (2008) Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J Virol 82: 9505-9512.
33. Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT (2013) Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol 87: 3862-3870.
34. Lipovsky A, Popa A, Pimienta G, Wyler M, Bhan A, et al. (2013) Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus. Proc Natl Acad Sci U S A 110: 7452-7457.
35. Bergant Marusic M, Ozbun MA, Campos SK, Myers MP, Banks L (2012) Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 13: 455-467.
36. Bronnimann MP, Chapman JA, Park CK, Campos SK (2013) A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection. J Virol 87: 464-473.
37. Day PM, Baker CC, Lowy DR, Schiller JT (2004) Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 101: 14252-14257. (Pubitemid 39305061)
38. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, et al. (2006) A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80: 759-768. (Pubitemid 43062888)
39. Pereira R, Hitzeroth, II, Rybicki EP (2009) Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol 154: 187-197.
40. Bergant M, Banks L (2013) SNX17 facilitates infection with diverse papillomavirus types. J Virol 87: 1270-1273.
41. Wang JW, Roden RB (2013) L2, the minor capsid protein of papillomavirus. Virology.
42. Kondo K, Ishii Y, Mori S, Shimabukuro S, Yoshikawa H, et al. (2009) Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. Virology 394: 259-265.
43. Barrowman J, Bhandari D, Reinisch K, Ferro-Novick S (2010) TRAPP complexes in membrane traffic: convergence through a common Rab. Nat Rev Mol Cell Biol 11: 759-763.
44. Lynch-Day MA, Bhandari D, Menon S, Huang J, Cai H, et al. (2010) Trs85 directs a Ypt1 GEF, TRAPPIII, to the phagophore to promote autophagy. Proc Natl Acad Sci U S A 107: 7811-7816.
45. Bassik MC, Kampmann M, Lebbink RJ, Wang S, Hein MY, et al. (2013) A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152: 909-922.
46. Behrends C, Sowa ME, Gygi SP, Harper JW (2010) Network organization of the human autophagy system. Nature 466: 68-76.
47. Scrivens PJ, Noueihed B, Shahrzad N, Hul S, Brunet S, et al. (2011) C4orf41 and TTC-15 are mammalian TRAPP components with a role at an early stage in ER-to-Golgi trafficking. Mol Biol Cell 22: 2083-2093.
48. Ishii Y, Tanaka K, Kondo K, Takeuchi T, Mori S, et al. (2010) Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. Virology 406: 181-188.
49. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358: 266-272. (Pubitemid 46136425)
50. Ozbun MA, Meyers C (1997) Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J Virol 71: 5161-5172. (Pubitemid 27258188)
51. Ozbun MA (2002) Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J Virol 76: 11291-11300. (Pubitemid 35231284)
52. Patterson NA, Smith JL, Ozbun MA (2005) Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79: 6838-6847. (Pubitemid 40677316)
53. Nonnenmacher M, Weber T (2011) Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10: 563-576.
54. Harper CB, Popoff MR, McCluskey A, Robinson PJ, Meunier FA (2013) Targeting membrane trafficking in infection prophylaxis: dynamin inhibitors. Trends Cell Biol 23: 90-101.
55. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, et al. (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77: 13125-13135. (Pubitemid 37494308)
56. Ethell IM, Hagihara K, Miura Y, Irie F, Yamaguchi Y (2000) Synbindin, A novel syndecan-2-binding protein in neuronal dendritic spines. J Cell Biol 151: 53-68.
57. Kakuta S, Yamamoto H, Negishi L, Kondo-Kakuta C, Hayashi N, et al. (2012) Atg9 vesicles recruit vesicle-tethering proteins Trs85 and Ypt1 to the autophagosome formation site. J Biol Chem 287: 44261-44269.
58. Surviladze Z, Sterk RT, DeHaro SA, Ozbun MA (2013) Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J Virol 87: 2508-2517.
59. Griffin LM, Cicchini L, Pyeon D (2013) Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes. Virology 437: 12-19.
60. Ishii Y (2013) Electron microscopic visualization of autophagosomes induced by infection of human papillomavirus pseudovirions. Biochem Biophys Res Commun 433: 385-389. Technology